欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
MMAF sodium_1799706-65-2_产品详情
1799706-65-2
  • names:

    MMAF sodium

  • CAS号:

    1799706-65-2

    MDL Number:
  • MF(分子式): C39H64N5NaO8 MW(分子量): 753.94
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
MMAF sodium
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM000926-5mg 5mg 99.73% ¥ 3915.00 ¥ 3915.00 2-3天
- +
¥ 0.00
YZM000926-2mg 2mg 99.73% ¥ 1950.00 ¥ 1950.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名 MMAF sodium
CAS号 1799706-65-2
Inchi
InchiKey
分子式 Formula C39H64N5NaO8
分子量 Molecular Weight 753.94
溶解度Solubility 生物体外In Vitro:DMSO溶解度≥ 200 mg/mL(265.27 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性状
储藏条件 Storage conditions 4°C, stored under nitrogen * In solvent : -80°C, 6 months月; -20°C, 1 month月 (stored under nitrogen)
产品说明
IntroductionMMAF sodium (Monomethylauristatin F sodium) is a potenttubulin polymerizationinhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibodyrug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGND19A[2][3].
Application1
Application2
Application3
MMAF sodium (Monomethylauristatin F sodium) 是一种有效的微管蛋白聚合 (tubulin polymerization) 抑制剂,用作抗肿瘤药物。MMAF sodium (Monomethylauristatin F sodium) 广泛用作抗体-药物偶联物 (ADCs) 的细胞毒性成分,如Vorsetuzumab mafodotin 和 SGN-CD19A。MMAF sodium (Monomethylauristatin F sodium) is a potenttubulin polymerizationinhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A[1][2][3].
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70.
【2】.Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12020-4.
【3】.Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics.
【4】.Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents